Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 3 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

0
Player Avatar TMFCandyMountain (99.79) Submitted: 1/29/2013 3:22:34 PM : Outperform Start Price: $10.29 ELN Score: +6.40

will show better profitability post spinoff

Featured Broker Partners


Advertisement